DelveInsight’s, “Schizophrenia Pipeline Insight 2023,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Schizophrenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Schizophrenia Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schizophrenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key Takeaways from the Schizophrenia Pipeline Report
To explore more information on the latest breakthroughs in the Schizophrenia Pipeline treatment landscape of the report, click here @ Schizophrenia Pipeline Outlook
Schizophrenia Overview
Schizophrenia causes psychosis and is associated with considerable disability and may affect all areas of life including personal, family, social, educational, and occupational functioning. It is thought that interaction between genes and a range of environmental factors may cause schizophrenia.
Recent Developmental Activities in the Schizophrenia Treatment Landscape
For further information, refer to the detailed Schizophrenia Unmet Needs, Schizophrenia Market Drivers, and Schizophrenia Market Barriers, click here for Schizophrenia Ongoing Clinical Trial Analysis
Schizophrenia Emerging Drugs Profile
Ulotaront: Otsuka Pharmaceutical
Ulotaront (SEP-363856), one of the first of a new class of CNS-active compounds, is an agonist at trace amine-associated receptor 1 (TAAR1) as well as serotonin 5-HT1A receptors. TAAR1 is a G-protein-coupled receptor expressed in cortical, limbic, and midbrain monoaminergic regions that modulate dopaminergic, serotonergic, and glutamatergic activity. In contrast to first- and second-generation antipsychotics, the efficacy of ulotaront is not mediated by blockade of D2 or 5-HT2A receptors. Ulotaront has demonstrated positive effects in rodent models assessing endophenotypes of schizophrenia, including phencyclidine (PCP)-induced hyperactivity, prepulse inhibition, and PCP-induced deficits in social interaction and cognition. An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia. It’s currently in phase III stage of development.
Luvadaxistat: Takeda
Luvadaxistat is a potential first-in-class, investigational, oral, selective inhibitor with a high binding affinity to d-amino acid oxidase (DAAO). It targets glutamate, an abundant neurotransmitter in the brain. In schizophrenia, N-methyl D-aspartate (NMDA) receptor hypofunction on PV+ gamma-aminobutyric acid (GABA) interneurons results in disinhibition of cortical or hippocampal glutamate neurons projecting to the pyramidal neurons. The cortical disturbances account for the negative/cognitive symptoms of schizophrenia, while the downstream subcortical dopamine release manifests as the positive symptoms of the disorder. A Phase II Randomized, Double-Blind, Placebo-Controlled, cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia is ongoing.
CY6463: Cyclerion Therapeutics
CY6463 is the first CNS-penetrant sGC stimulator to be developed as a symptomatic and potentially disease-modifying therapy for serious CNS diseases. The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that precisely controls key aspects of physiology throughout the body. Cyclerion Therapeutics has initiated a double-blinded, randomized, placebo-controlled, multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants with Stable Schizophrenia.
AVP 786: Avanir Pharmaceuticals
Deudextromethorphan (AVP 786) is a combination product of a deuterium-containing analogue of dextromethorphan and an ultra-low dose of quinidine, that is being developed by Avanir Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals), under a license from Concert Pharmaceuticals, for the treatment of psychiatric and Neurological Indications. Currently it is being evaluated in phase II/III stage of development for the treatment of schizophrenia.
Schizophrenia Pipeline Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Schizophrenia. The companies which have their Schizophrenia drug candidates in the most advanced stage, i.e. phase III include, Otsuka Pharmaceutical.
Request a sample and discover the recent advances in Schizophrenia Ongoing Clinical Trial Analysis and Medications, click here @ Schizophrenia Treatment Landscape
Scope of the Schizophrenia Pipeline Report
Dive deep into rich insights for drugs for Schizophrenia Market Drivers and Schizophrenia Market Barriers, click here @ Schizophrenia Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Schizophrenia Mergers and acquisitions, Schizophrenia Licensing Activities @ Schizophrenia Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
